RxDoctor Payments Data

Hamza Tantoush

Rheumatology · Pikeville, KYNPI 1669737862

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $635, 2.1 times the $297 reported in 2019. That places this record below the midpoint for rheumatology clinicians in KY, where the typical reported total is $2,001.

$1,613in general payments, 2019–2025

Across 74 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$351
  • Merck$155
  • Dexcom, Inc.$145
  • Sanofi-aventis U.S. LLC$125
  • Boehringer Ingelheim$102
  • UCB, Inc.$89
  • plus $646 from 18 others

What the payments were for

  • Food & beverage$1,613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,613 in reported general payments places this provider in the 40th percentile of 81 rheumatology providers in Kentucky.

See all rheumatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$17,005
Medicare patients
101
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab46$296,413
Enbrel SureclickEtanercept39$279,999
Humira PenAdalimumab14$97,876
RinvoqUpadacitinib15$91,936
Orencia ClickjectAbatacept13$75,493
OtezlaApremilast16$75,284
Hydroxychloroquine Sulfate143$3,256
MethotrexateMethotrexate Sodium87$1,112
Leflunomide15$1,093
Sulfasalazine DrSulfasalazine26$732
Alendronate Sodium65$204
Prednisone41$193
Azathioprine15$156
Folic Acid15$51
Vitamin D2Ergocalciferol (Vitamin D2)13$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$54$91,93615 claims
AmgenOtezla$351$75,28416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 81 rheumatology providers in Kentucky.

Other rheumatology in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →